3D Bioprinting in Anterior Segment Ocular Tissue Engineering: Advances, Challenges, and Translational Pathways-A Systematic Review

Abstract
Bioprinting has been proposed for nearly every structure of the anterior eye, but the effort is unevenly spent. We systematically reviewed 71 experimental studies of bioprinting across the anterior segment: cornea, conjunctiva, sclera, lens, lacrimal gland and eyelid. Most work targets the corneal stroma. The endothelium, the layer most often replaced surgically and the first to reach a clinical trial, accounts for the fewest preclinical studies. Beyond the cornea, printed constructs are mostly disease models rather than implants, and the iris, trabecular meshwork and ciliary body remain untouched. Preclinical testing remains short-term and confined to small animals. Studies measure the same properties in different ways, so constructs cannot be compared across laboratories. We map what has been printed for each tissue and how far each construct stands from the clinic, and propose a minimum reporting set to make the next generation of studies comparable.
From the paper
- Harms
At four weeks, cell-laden scaffolds supported reconstruction of the posterior lamella, expressed meibocyte differentiation markers (SREBP-1, PPAR-γ, FADS2 and FAS), and produced no adverse events in any operated eyelid.
Results, 3.3.5. Eyelid, Meibomian Gland and Nasolacrimal System
- Limitation
The search covered only PubMed and Scopus and was restricted to English, so eligible studies in other databases or languages may have been missed.
Quoted word for word from the full text on PubMed Central.
The paper
Aristotle University of Thessaloniki; University of Miami
Cells, 17 Sep 2026, Open access
